Evidence map›Paper›PMID 40384974›Full record

ReviewFrontiers in cellular and infection microbiology2025

Advancements in AI-driven drug sensitivity testing research.

Hongxian Liao, Lifen Xie, Nan Zhang, Jinping Lu, Jie Zhang

Abstract readReview
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. [Advances in the Application of Artificial Intelligence in Clinical Microbiological Testing].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026
    Review
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hongxian LiaoDepartment of Radiology, Zhuhai People's Hospital, The First School of Clinical Medicine of Guangdong Medical University, Zhuhai, China.
Lifen XieDepartment of Radiology, Zhuhai People's Hospital (Zhuhai Hospital affiliated to Jinan University), Zhuhai, China.
Nan ZhangDepartment of Oncology, Zhuhai People's Hospital (Zhuhai Hospital affiliated to Jinan University), Zhuhai, China.
Jinping LuDepartment of Clinical Laboratory and Medical Research Center, Zhuhai People's Hospital(Zhuhai Hospital affiliated to Jinan University), Zhuhai, China.
Jie ZhangDepartment of Radiology, Zhuhai People's Hospital, The First School of Clinical Medicine of Guangdong Medical University, Zhuhai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance (AMR) constitutes a significant global public health challenge, posing a serious threat to human health. In clinical practice, physicians frequently resort to empirical antibiotic therapy without timely Antimicrobial Susceptibility Testing (AST) results. This practice, however, may induce resistance mutations in pathogens due to genetic pressure, thereby complicating infection control efforts. Consequently, the rapid and accurate acquisition of AST results has become crucial for precision treatment. In recent years, advancements in medical testing technology have led to continuous improvements in AST methodologies. Concurrently, emerging artificial intelligence (AI) technologies, particularly Machine Learning(ML) and Deep Learning(DL), have introduced novel auxiliary diagnostic tools for AST. These technologies can extract in-depth information from imaging and laboratory data, enabling the swift prediction of pathogen antibiotic resistance and providing reliable evidence for the judicious selection of antibiotics. This article provides a comprehensive overview of the advancements in research concerning pathogen AST and resistance detection methodologies, emphasizing the prospective application of artificial intelligence and machine learning in predicting drug sensitivity tests and pathogen resistance. Furthermore, we anticipate future directions in AST prediction aimed at reducing antibiotic misuse, enhancing treatment outcomes for infected patients, and contributing to the resolution of the global AMR crisis.

Indexed as

Anti-Bacterial AgentsArtificial IntelligenceBacteriaDeep LearningDrug Resistance, BacterialHumansMachine LearningMicrobial Sensitivity TestsAnti-Bacterial Agentsantimicrobial resistanceantimicrobial susceptibility testingartificial intelligencemachine learningwhole genome sequencing

Identifiers

PMID40384974
PMCPMC12081381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.